Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NITO
stocks logo

NITO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for N2OFF Inc (NITO.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess N2OFF Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.17
Current EV/EBITDA
4.96
Overvalued EV/EBITDA
2.44
Undervalued EV/EBITDA
-2.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.08
Current PS
0.94
Overvalued PS
13.28
Undervalued PS
-3.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NITO News & Events

Events Timeline

(ET)
2025-11-18
09:39:32
CEO Silberman Provides Update on N2OFF
select
2025-10-30 (ET)
2025-10-30
09:26:47
N2OFF Finalizes Merger with MitoCareX Bio
select
2025-10-23 (ET)
2025-10-23
08:28:01
N2OFF Completes Merger with MitoCareX Bio
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-18Newsfilter
N2OFF: MitoCareX Discovers Promising Compounds and Targets for Preclinical Candidate Selection

  • Company Acquisition and Strategic Direction: N2OFF, Inc. has acquired MitoCareX Bio Ltd., with CEO Dr. Alon Silberman outlining the company's focus on precision oncology and the development of novel therapies targeting aggressive cancers using their proprietary MITOLINE™ algorithm.

  • Innovative Drug Discovery Approach: MitoCareX is leveraging MITOLINE™ for drug discovery, aiming to create first-in-class therapeutics that disrupt cancer metabolism, particularly for lung and pancreatic cancers, which represent a significant market opportunity.

  • Short-Term and Long-Term Goals: The company plans to optimize hit compounds and prepare for preclinical development in 2026, while also exploring strategic collaborations to expand MITOLINE™'s applications and generate non-dilutive revenue.

  • Future Outlook and Mission: MitoCareX aims to establish itself as a leader in drug discovery by focusing on mitochondrial biology and precision oncology, with a mission to transform insights into value for patients and shareholders through a scalable discovery platform.

[object Object]
Preview
8.5
10-30Newsfilter
N2OFF Finalizes Merger with Cancer Drug Discovery Firm Focused on Challenging Pancreatic and Lung Cancers

  • Merger Announcement: N2OFF, Inc. has completed its merger with MitoCareX Bio Ltd, a biotech company focused on cancer therapeutics, enhancing N2OFF's portfolio in the cleantech and biotech sectors.

  • MitoCareX's Focus: MitoCareX is developing novel therapies targeting mitochondrial SLC25 proteins to treat hard-to-treat cancers, utilizing its proprietary MITOLINE™ algorithm for drug discovery.

  • Financial Details: N2OFF acquired MitoCareX for $700,000 and common stock representing 40% of N2OFF's fully diluted capital stock, with additional financial commitments to support MitoCareX's operations for two years.

  • Market Potential: The global cancer therapeutics market is projected to grow from $211.02 billion in 2025 to $378.62 billion by 2032, indicating significant opportunities for MitoCareX's innovations in cancer treatment.

[object Object]
Preview
8.5
09-30NASDAQ.COM
SciSparc Shares Jump 50% in Pre-Market Following N2OFF's Approval of MitoCareX Acquisition

  • Acquisition Approval: SciSparc Ltd. shares surged over 58% after N2OFF Inc. stockholders approved the acquisition of SciSparc's subsidiary, MitoCareX Bio Ltd., which will become wholly owned by N2OFF.

  • Financial Terms of the Deal: N2OFF will purchase MitoCareX for $0.7 million and exchange shares with the sellers, who will also receive 30% of financing proceeds raised by N2OFF for five years, up to $1.6 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is N2OFF Inc (NITO) stock price today?

The current price of NITO is 3.02 USD — it has decreased -1.31 % in the last trading day.

arrow icon

What is N2OFF Inc (NITO)'s business?

N2OFF Inc. is a clean tech company, which is engaged in providing sustainable solutions for agri- tech. The Company is focused on sustainable operations in various industries, such as agri-food tech, potent greenhouse gas emissions and solar projects, specialized in eco-crop protection that helps reduce food waste and ensure food safety while reducing the use of pesticides. Its solutions are based on a blend of food acids combined with certain types of oxidizing agent-based sanitizers and, in some cases, with fungicides at low concentrations. Its products have a synergistic effect when combined with these oxidizing agent-based sanitizers and fungicides. Its green solutions are capable of cleaning, sanitizing and controlling pathogens in fresh produce. The Company’s products include Processing Aids-SavePROTECT or PeroStar, which are an application added to fruit and vegetable wash water as a processing aid to peracetic acid to increase its efficiency against plant pathogens.

arrow icon

What is the price predicton of NITO Stock?

Wall Street analysts forecast NITO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NITO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is N2OFF Inc (NITO)'s revenue for the last quarter?

N2OFF Inc revenue for the last quarter amounts to 66.00K USD, increased 50.58 % YoY.

arrow icon

What is N2OFF Inc (NITO)'s earnings per share (EPS) for the last quarter?

N2OFF Inc. EPS for the last quarter amounts to -0.07 USD, decreased -73.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for N2OFF Inc (NITO)'s fundamentals?

The market is revising No Change the revenue expectations for NITO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -58.70%.
arrow icon

How many employees does N2OFF Inc (NITO). have?

N2OFF Inc (NITO) has 3 emplpoyees as of December 13 2025.

arrow icon

What is N2OFF Inc (NITO) market cap?

Today NITO has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free